Psilocybin
Terran Biosciences Files New Patent on First Salts and Polymorphs for 4-OH-DiPT
A PCT patent application from Terran Biosciences was just published covering their discovery of novel salts and polymorphs of the compound 4-OH-DiPT.
The…
A PCT patent application from Terran Biosciences was just published covering their discovery of novel salts and polymorphs of the compound 4-OH-DiPT, adding another layer of IP intrigue around the lesser-known but potentially important compound.
Salts and Solid Forms of 4-Hydroxy-N,N-Diisopropyltryptamine Hemi-Glutarate and Hemi-Succinate was filed by Terran Biosciences and has claims on salts and polymorphs of 4-OH-DiPT, the same compound that both Mindset Pharma and Reunion Neuroscience have applied for patent claims on.
4-HO-DiPT is a psilocybin-like compound initially researched by the Shulgins and noted for its intense effects and shorter onset and trip time. Reunion and Mindset have been competing over patent claims on this drug, with Reunion recently suing Mindset Pharma over its competing patent.
Terran has been quite busy expanding its development portfolio and IP strategy with several recent announcements (see below). This recent publication marks another milestone from Terran’s chemistry team who have built a robust solid-state chemistry platform. So while companies like Reunion and Mindset Pharma have been publicly dueling over the IP around this compound, it appears that Terran had been working on making advances to the compound’s chemistry and developing these novel approaches that, to our knowledge, others have not yet pursued.
While Terran is developing many compounds in-house, they have announced that they’ve made large data packages and IP portfolios available for licensing and partnerships to help advance the psychedelic industry as a whole, which would certainly be of interest to other companies looking to accelerate the development of their pipelines.
For more on Terran, check out Terran Biosciences announces publication of four patent applications of novel empathogens and Terran Biosciences Announces Licensing Deal with Pierre Fabre for Idazoxan; Completes Development Milestones
The post Terran Biosciences Files New Patent on First Salts and Polymorphs for 4-OH-DiPT appeared first on Microdose.
psilocybin psychedelic deal mindset pharma mindset
-
Psilocybin1 week agoCalifornia advances bill for psychedelics centers
-
Psilocybin6 days agoPassover Perspectives: Psychedelics, Moses, and the Burning Bush
-
Psychedelics1 week agoPsychedelics Can Offer More Than Therapy On Its Own
-
Psychedelics5 days agoAlgernon NeuroScience and the Centre for Human Drug Research to Present DMT Phase 1 Stroke Clinical Data at the Interdisciplinary Conference on Psychedelic Research June 6 – 8th, 2024
-
Psychedelics6 days agoRevive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID
-
Law & Regulation5 days agoTryp Therapeutics merger with Exopharm approved by shareholders
-
Psychedelics5 days agoatai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech’s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression
-
Psychedelics6 days agoSilo Pharma Announces Positive Results for Intranasal PTSD Treatment